Results 11 to 20 of about 3,689 (149)

The participation of the muscarinic receptors in the preoptic-anterior hypothalamic areas in the regulation of ovulation depends on the ovary

Reproductive Biology and Endocrinology, 2016
Background Muscarinic receptors (mAChRs) of the preoptic and anterior hypothalamus areas (POA-AHA) regulate ovulation in an asymmetric manner during the estrous cycle.
Adriana Espinosa-Valdez, Angélica Flores, Isabel Arrieta-Cruz, Mario Cárdenas, Roberto Chavira, Roberto Domínguez, María Esther Cruz   +6 more
doaj   +1 more source

Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer

Reproductive Biology and Endocrinology, 2003
The expression of GnRH (GnRH-I, LHRH) and its receptor as a part of an autocrine regulatory system of cell proliferation has been demonstrated in a number of human malignant tumors, including cancers of the ovary.
Emons Günter, Gründker Carsten
doaj   +1 more source

Involvement of Membrane Progestin Receptor Beta (mPRβ/Paqr8) in Sex Pheromone Progestin-Induced Expression of Luteinizing Hormone in the Pituitary of Male Chinese Black Sleeper (Bostrychus Sinensis)

Frontiers in Endocrinology, 2018
Our previous studies showed that 17α, 20β-dihydroxy-4-pregnen-3-one (DHP) acted as a sex pheromone to induce reproductive success in Chinese black sleeper (Bostrychus sinensis), but its functional mechanism remains unclear.
Yu Ting Zhang, Wan Shu Hong, Dong Teng Liu, Heng Tong Qiu, Yong Zhu, Yong Zhu, Shi Xi Chen, Shi Xi Chen, Shi Xi Chen   +8 more
doaj   +1 more source

AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors

Expert Opinion on Investigational Drugs, 2012
Receptors for the luteinizing hormone-releasing hormone [LHRH, also known as gonadotropin-releasing hormone (GnRH)] can be regarded as an ideal target for a personalized medicine approach in cancer therapy. LHRH receptors are expressed in about 80% of human endometrial and ovarian cancers, 86% of prostate cancer, and about 50% of breast cancers ...
Engel, Joerg B., Emons, Guenter, Pinski, Jacek, Schally, Andrew V.   +3 more
openaire   +3 more sources

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.

PLoS ONE, 2012
Almost all prostate cancers respond to androgen deprivation treatment but many recur. We postulated that risk of hormone escape--frequency and delay--are influenced by hormone therapy modalities.
Charlotte Guyader, Jocelyn Céraline, Eléonore Gravier, Aurélie Morin, Sandrine Michel, Eva Erdmann, Gonzague de Pinieux, Florence Cabon, Jean-Pierre Bergerat, Marie-France Poupon, Stéphane Oudard   +10 more
doaj   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

Changes in pituitary and ovarian LHRH receptors after active immunization of female rats against LH or LHRH [PDF]

Reproduction, 1985
Summary. The hypothalamic—pituitary—ovarian axis of female rats was disrupted at the site of LHRH stimulation by active immunization against LHRH or at the site of LH action by active immunization against LH. Active immunization against LH was associated with an increase in pituitary LHRH receptors to levels comparable to control ...
R M, Popkin, H M, Fraser
openaire   +2 more sources

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Complete Response to Concurrent Triplet Therapy in Low‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: A Case Report

IJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Triplet therapy with androgen deprivation therapy (ADT), an androgen receptor pathway inhibitor, and docetaxel improves survival in metastatic hormone‐sensitive prostate cancer (mHSPC), but its role in low‐volume disease remains unclear.
Takashi Fujita, Koki Kobayashi, Gaku Hayashi, Shunsuke Kamijo, Fumihiro Ito   +4 more
wiley   +1 more source